

# PacBio HiFi WGS identifies potential causal P16.011.D variants not found by short-read sequencing

William J Rowell<sup>\*1</sup>, Shelby Redfield<sup>2</sup>, Cillian Nolan<sup>1</sup>, J Matthew Holt<sup>1</sup>, Xiao Chen<sup>1</sup>, Cairbre Fanslow<sup>1</sup>, Eirini Maria Lampraki<sup>1</sup>, Christine Lambert<sup>1</sup>, Chris Saunders<sup>1</sup>, Margaret A Kenna<sup>2,3</sup>, Eliot Shearer<sup>2,3</sup>, Michael A Eberle<sup>1</sup>

1. Pacific Biosciences, Menlo Park, United States, 2. Boston Children's Hospital, Otolaryngology & Communication Enhancement, Boston, United States, 3. Harvard Medical School, Otolaryngology Head and Neck Surgery, Boston, United States

## Background

- It is estimated that 60% of pediatric hearing loss cases have genetic cause.
- There are 124 known non-syndromic hearing loss genes and ~400 syndromic forms of hearing loss.
- Gene panels and short-read NGS are standard of care for pediatric hearing

# Methods

- BCH clinicians provided blood derived DNA from 10 probands with sensorineural hearing loss (1 unilateral, 9 bilateral) that was unexplained by srWES and srWGS.
- 12–15 kb insert SMRTbell libraries were prepared and sequenced to 24– to 32– fold coverage on the Sequel II system.
- Sequence data was processed by an automated workflow described below.

### loss.

- Traditional short read whole exome sequencing (srWES) explains ~40% of cases.
- Copy number variations (CNVs) in the STRC region are the most common cause of mild-moderate hearing loss in children.
- PacBio HiFi reads (99.9% accuracy, 15-20 kb) enable comprehensive variant detection in human genomes, extending to repetitive regions of the genome not accessible with shortread WGS (srWGS) or WES (srWES).
- HiFi reads match or surpass srWGS for single nucleotide variant and small indel (<50 bp) detection while also improving detection of structural variants (SVs, ≥50 bp), with recall far exceeding that of srWGS.



• Here we apply HiFi-WGS to 10 probands with unexplained hearing loss who had previously undergone srWES and srWGS with a negative result.

### Results

- We identified a median of 4,505,589 SNVs, 981,037 small indels, and 22,682 SVs per sample.
- Variants of phenotypic interest were identified in 7 cases, with 3 cases explained: 1) a compound heterozygous 769 bp deletion and A>G missense variant in OTOA, 2) a compound heterozygous ~104 kb deletion and G>A stop-gain variant in STRC, and 3) a copy number neutral 403 kb inversion interrupting *MITF*.



#### Identification of compound heterozygous

pathogenic variants in STRC. Depth-based CNV caller HiFiCNV detected a 104 kb deletion (approx. chr15:43,566,001-43,670,000) covering *STRC*. On the other allele, DeepVariant identifies chr15:43,616,338 G>A (absent from gnomAD, ClinVar, and LOVD), resulting in a stop gain in an exon that is challenging to



Identification of inversion interrupting MITF. In haplotype 1, structural variant caller pbsv detected a 403 kb inversion (chr3:69,927,910-70,331,155) interrupting *MITF*. Haplotype 1 is shown twice, once with primary and supplementary linked to demonstrate that reads align to opposite strands, indicating an inversion.





#### Identification of compound heterozygous

pathogenic variants in OTOA. In haplotype 1, structural variant caller pbsv detected a 769 bp deletion at chr16:21,735,945 covering exon 22 of OTOA. In haplotype 2, DeepVariant identifies chr16:21,744,915 A>G (absent in gnomAD and ClinVar; VUS in LOVD), a missense variant in an exon that is challenging to map with short reads. These variants are shown to be *in* trans.



Visualization of STRC & STRCP1 haplotypes identified by Paraphase. Paraphase (P18.025.A) is a HiFi-based informatics method that can accurately genotype variants in gene/paralog pairs. Reads from both STRC and pseudogene STRCP1 are aligned to STRC in the reference and grouped by haplotype. Paraphase identifies only one STRC haplotype, with roughly half of the expected coverage (CN1), containing a G>A stop gain at chr15:43,616,338.

### Conclusion

HiFi-WGS increases the ability to explain rare disease cases by allowing for the detection of a broad range of variants, especially in regions that are difficult to map with srWGS.



Contact: wrowell@pacb.com

Conflict of interests: WJR, CN, JMH, XC, CF, EML, CL, CS, and MAE are employees and shareholders of PacBio.

Research use only. Not for use in diagnostic procedures. © 2023 Pacific Biosciences of California, Inc. ("PacBio"). All rights reserved. Information in this document is subject to change without notice. PacBio assumes no responsibility for any errors or omissions in this document. Certain notices, terms, conditions and/or use restrictions may pertain to your use of PacBio products and/or third-party products. Refer to the applicable PacBio terms and conditions of sale and to the applicable license terms at pacb.com/license. Pacific Biosciences, the PacBio logo, PacBio, Circulomics, Omniome, SMRT, SMRTbell, Iso-Seq, Sequel, Nanobind, SBB, Revio, and Onso are trademarks of PacBio.